Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 24nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair